Medicare coverage of Novo Nordisk’s Wegovy could cost up to $145B annually

Two packages of a fictitious Semaglutide drug used for weight loss (antidiabetic or anti-obesity medication) on a blue transparent background. Fictitious package design. Two dosing pens in front.

aprott/iStock via Getty Images

Novo Nordisk’s (NVO) weight-loss drug Wegovy (semaglutide), which can be prescribed to Medicare beneficiaries with obesity and cardiovascular disease, could cost the system up to $145 billion a year.

If all eligible beneficiaries receive Wegovy

The post Medicare coverage of Novo Nordisk’s Wegovy could cost up to $145B annually first appeared on Investorempires.com.